Vitae Pharmaceuticals (VTAE) Tops Q1 EPS by 7c

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q1 EPS of ($0.44), $0.07 better than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation